| Name | Title | Contact Details |
|---|
Mitsubishi Polyester Film is a leading supplier of polyester (PET) film, part of Mitsubishi Chemical America, Inc. The company operates manufacturing sites in the USA, Europe, Japan, Indonesia, and China, with a total global capacity of 250,000 tons. It specializes in biaxially oriented polyester (boPET) films, offering a range of thicknesses and polymer types for various applications. Key brands include Hostaphan® and Diafoil®. The company emphasizes vertical integration, with on-site PET resin manufacturing and over 50 coating types. It also focuses on sustainability through initiatives like the REPROCESS™ recycling program, which incorporates post-industrial recycled content. Mitsubishi Polyester Film provides customized solutions through its global R&D efforts, addressing product design, manufacturing, logistics, and process challenges.
Starr Insurance is a prominent part of Starr Companies, a global insurance and investment organization founded in 1919 by Cornelius Vander Starr. Initially established as the first American-owned insurance agency in Shanghai, the company has grown to operate across six continents, becoming a significant player in the insurance industry. Starr Insurance offers a diverse range of products and services, including commercial property and casualty insurance, as well as specialty coverages such as aviation, marine, energy, and excess casualty insurance. The company serves a wide array of clients, including leading businesses in sectors like construction, maritime, energy, and aerospace. With its extensive global presence, Starr Insurance is well-equipped to provide comprehensive insurance solutions tailored to the needs of businesses worldwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Were developing tech to feed the world. The world is running out of phosphorus. Most of the worlds phosphorus is used to grow food to feed to animals to produce meat. Manure isnt returned to growing regions, and instead leads to algal blooms and nutrient pollution. Were fixing this problem with tech to produce fertilizer from manure, helping farmers grow better food at a price farmers can afford.
Bigelow is the M + A Advisor exclusively for owners of high-performing private companies — Entrepreneur Owner-Managers with their skin in the game. Our scrappy boutique firm behaves as one collaborative team. Leveraging our independence and exclusive EOM focus, we have helped hundreds of clients build and capture Enterprise Value while respecting their values, their legacy and the intersection of their professional and personal goals. Frequently our work with clients goes on for years in advance of a wealth-building transaction. Unlike virtually all of the firms with which we compete, we are independently owned. We have only one source of revenue — our Entrepreneur Owner-Manager clients. No referral fees. No investing, trading, lending, or underwriting. No buy-side advisory. No products to sell. No conflicts. We aspire to be completely aligned with achieving our clients potential, striving endlessly to be masters of our craft.